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Abstract 
Colorectal cancer (CRC) is one of the most common cancers globally and is associated 
with a high rate of morbidity and mortality. A large proportion of patients with early stage 
CRC who undergo conventional treatments develop local recurrence or distant 
metastasis and in this group of advanced disease, the survival rate is low. Furthermore 
there is often a poor response and/or toxicity associated with chemotherapy and 
chemo-resistance may limit continuing conventional treatment alone. Choosing novel 
and targeted therapeutic approaches based on clinicopathological and molecular 
features of tumors in combination with conventional therapeutic approach could be used 
to eradicate residual micrometastasis and therefore improve patient prognosis and also 
be used preventively. Peptide-based vaccination therapy is one class of cancer 
treatment that could be used to induce tumor-specific immune responses, through the 
recognition of specific antigen-derived peptides in tumor cells, and this has emerged as 
a promising anti-cancer therapeutic strategy. The aim of this review was to summarize 
the main findings of recent studies in exciting field of peptide-based vaccination therapy 
in CRC patients as a novel therapeutic approach in treatment of CRC. 
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Introduction 
Colorectal cancer (CRC) is one of the most common cancers globally, and 
accounts for a high rate of morbidity and mortality (1), and can severely impair quality of 
life (2). It is accounted that annually greater than one million new cases are diagnosed 
world-wide (3). The CRC incidence rate varies geographically, however in men and 
women are affected nearly equal (4, 5). In some regions like United States, several 
European countries, Canada, Australia, and New Zealand the incidence rate is high. In 
contrast, in East and central Asia and some parts of Africa and South America it has 
been observed to have low incidence rate (4, 6). Positive family history, presence of 
some specific genetic properties, age, obesity, inflammatory bowel disease and over-
consumption of alcohol and red meat are considered to be an important risk factors for 
CRC (7-9). The CRC incidence and its related mortality has started to decrease in high-
income countries and also in individuals over the age of fifty, however this has 
continued to increase in low-income countries and under the age of 50 (10). The patient 
survival rate is highly dependent on the stage at diagnosis and treatment, being 
approximately 90% in patients who undergo treatment in the early stages (stage I and 
II) whilst roughly 70% in patients with regional lymph node metastasis and less than 
10% in distant metastatic disease (3, 11). CRC patients are commonly treated with 
similar chemoradiotherapeutic and surgical protocol (12). Despite many advances that 
have occurred during the last few years in the detection and successful therapeutic 
approach in early stage, a large proportion of CRC patients diagnosed and treated in 
the early stages ultimately develop recurrence or distant metastasis (13, 14). 
Furthermore the poor response to chemotherapy, and the toxicity and chemo-resistant 
cancer has limited the benefits of conventional treatment alone. With respect to 
variation in clinicopathological and molecular features of tumors between CRC patients 
to patients, choosing novel and specific therapeutic approaches based on these 
differences in combination with conventional therapeutic approach could eradicate 
residual micrometastasis and therefore improve patient prognosis and also serving as a 
preventive measure. Recently immunotherapy using cancer vaccines have entered 
trials in a variety of cancers as a promising anti-cancer therapeutic strategy and has 
shown impressive clinical benefit due to being well tolerated and being without dose-
limiting toxicities (15, 16).  
Peptide-based vaccination therapy is one type of cancer vaccines which has 
been investigated in CRC treatment (17). This form of vaccine induce tumor-specific T 
cell mediated immune responses through recognition of specific antigen-derived 
peptides in tumor cells (17). Regarding recent advances in the genetic based research, 
personalized medicine is a growing field which is findings its place within the vast 
majority of developing sciences. In cancer research, there have been benefits from this 
new approach to personalized medicine in term of treatment and diagnosis. 
Personalized vaccine therapy is an emerging field in cancer treatment. In this therapy, 
according to recent status of patient’s immune system and some other individual tumor 
factors, a more specific and potent vaccine is developed for specific individuals (18) 
(Figure 1). The aim of this review is to summarize the main findings of recent studies in 
exciting field of peptide-based vaccination therapy in CRC patients as a novel 
therapeutic approach in treatment of CRC.  
 
 Conventional treatment of colorectal cancer 
Treatment of colorectal cancer relies on disease stage and involves a 
multidisciplinary approach (2, 19, 20). Treatment depends on three main approaches: 
surgery, chemotherapy and radiotherapy. Surgical treatment is the main curative 
treatment in non-metastasized CRC patients (stage I and II) (21). During surgical 
treatment; in addition to tumoral tissue removal, a small margin of surrounding tumor 
free tissue and adjacent lymph node are removed (22). Based on several conditions 
including patient’s general health, surgeon’s experience and available equipment in 
surgical center, tumor resection can be done by laparoscopic resection or open surgery. 
Preoperative chemotherapy and/or radiotherapy, also called neoadjuvant treatment, can 
decrease tumor size and local recurrence and increase chance of successful tumor 
resection (23). Adjuvant treatment, also known as postoperative chemoradiotherapy, 
improves survival after surgical treatment (24). The most common protocol used in 
chemotherapy is the FOLFOX protocol (consists 5-Fluorouracil, Folinic Acid 
(Leucovorin) and Oxaliplatin) and CapeOx protocol (consists capecitabine and 
oxaliplatin) (24). When tumoral cells have spread to regional lymph nodes (CRC stage 
III) partial colectomy is usually accompanied by surgical removal of metastatic lymph 
nodes. Furthermore, in these patients adjuvant chemotherapy can improve outcomes 
(2). In CRC stage IV in which cancerous cells are involve distant organs and lymph 
nodes, surgery in most patients is not possible, however it can be effective if both the 
primary tumor and distant metastases are small and resectable (25). In these patients, 
chemoradiotherapy is the mainstay therapy, to reduce symptoms and prolong survival. 
With the aim of improving survival, conventional therapies could be combined with 
immunotherapy which is less toxic, well-tolerated and more effective therapeutic 
approach to eradicate residual CRC cells especially in metastatic CRC. 
 
Cancer vaccines as a novel immunotherapeutic approach in colorectal cancer 
The early consideration of using cancer vaccines was reported in late 19th when 
the first allogeneic melanoma lysates were used as cancer vaccine (26). Later on, 
researchers have focused on designing more specific and effective vaccines for many 
other types of cancers and in 2010, the first cancer vaccine was approved by the USA’s 
Federal Drug Administration for prostate cancer (27). The rapid improvement of 
developing different types of vaccines is still ongoing and new types of genetic vaccines 
such as neoantigen based vaccines are under active research in clinical trials (28). 
According to available the strategies for developing cancer vaccines, cancer vaccine 
can be categorized into 3 main types. Dendritic cell vaccines (DCVs) are considered as 
an efficient approach among cancer vaccines. DCVs essentially use the human immune 
system to fight against cancers. During this approach, dendritic cells (DC) which are 
one of the antigen presenting cells and T lymphocytes which are responsible for cell-
mediated immunity will become involved (29). After a leukapheresis, DCs are maturated 
and presented with a specific tumor antigen ex vivo. Then these antigen-plused DCs 
are returned to the patient and present their tumor antigen to T lymphocytes (29). 
Allogeneic whole tumor cell lysate have been used in human CRC and achieved 
notable success. Toh et al. have loaded DCs with melanoma cell lysate which were 
expressing melanoma-associated antigen gene and delivered them to advanced CRC 
patients (30). Using the DCV approach results in boosting the human immune system 
response against tumor cells. In order to increasing the efficacy and overcoming the 
limitation of DCVs, researchers have tried different approaches. The main drawback of 
these types of vaccines which has to be overcome is the need for long term culturing 
DCs which was solved by using different DC subtypes. Also, by using neoantigens and 
whole tumor antigens, they could achieve a more favorable immune response against 
tumor antigens (31). The second type of cancer vaccines are termed as genetic 
vaccines (28). The major advantage of this type of vaccines in contrast to DCVs is the 
ability of delivering multiple types of antigens to a desired cell (32). During this method, 
plasmid DNA vectors which carry a desired antigen sequence are transferred to human 
cells which are mostly DCs. Expression of these gene cassettes results in the 
presentation of antigens to the immune system (32). DNA vaccines has been previously 
applied in colorectal cancer. A plasmid encoding the carcinoembryonic antigen (CEA) 
gene was given along with cyclophosphamide intramuscularly or intradermaly. The 
vaccine was well tolerated and only minor adverse events such as myalgia, fatigue and 
headache was reported (33). The major limitation of DNA vaccines is some problems 
with their efficacy and safety in contrast to DCVs. The expression of the desired 
cassette is not always achieved and fusion of the DNA into the human genome may be 
a limiting issues (34). mRNA vaccines have resolved some of these limitations but 
achieving a stable and long lasting RNA is remains a problem (35). Researchers have 
also used viruses as a possible cancer vaccine (36). Viruses can act as both vectors 
and oncolytics. However, these viral assistants still leave a safety issue which was 
previously noted with respect to DNA vaccines (37). The third group of cancer vaccines 
are peptide vaccines. This type of vaccine uses tumor associated antigen peptides to 
activate immune system. Single and multiple peptide vaccines have been used in 
cancer patients. The personalized peptide vaccine (PPV) is a new way in treating 
cancer. During this type of vaccination, there is a rapid and strong secondary immune 
response that develops according to pre-existing immunity in a cancer patient. Table 1 
has summarized the main differences between using personalized vaccines and 
common vaccines. 
 
The mechanism of anti-tumor effect of peptide-based vaccination therapy 
Traditional vaccination is usually performed by injecting a whole pathogen or its 
cellular membrane into a human body intramuscularly, subcutaneously or even by 
gastro intestinal tract such as oral Polio vaccines. Although peptide vaccination shares 
a similar approach as traditional vaccines, there are some special characteristics that 
have made it a potent vaccine even in treating non communicable diseases such as 
cancer. Regardless of vaccine type, almost all types of vaccines affect the human 
immune system. Tumor cells have antigens that are shared with viruses or bacterial 
pathogens which have potential to be used as vaccines. Antigen presenting cell in 
human circulating system uptake and process these protein antigens (38). These 
processed peptides will be presented to other immune system’s cells; lymphocytes. T 
cell lymphocytes can be a cytotoxic T lymphocyte (CD8+) or helper T lymphocytes 
(CD4+). The cytotoxic T cells have the ability to recognize and directly attack tumor 
cells. These cells have the ability to kill tumor cells through inducing apoptosis, 
releasing perforins and geransymes (39). T helper lymphocytes can release cytokines 
which are used to recruit more immune cells, especially natural killer cells (Figure 2).  
The peptides used as vaccines act in a similar manner. These peptides are 
mostly unique tumor associated antigens (TAAs). TAAs which are result of cancerous 
mutations are potentially a strong immune system activators in most tumors (40). 
However, the rapid changes in tumor cell populations and the development of new 
mutations because of altered repair mechanisms in tumor cells, make it possible to 
introduce new TAA with less immunogenicity. The best approach in choosing a TAA, is 
choosing the most immunogenic forms. The more specific the selected epitope, the 
more specific the result would be. Choosing the best epitopes should also be directed 
toward the desired immune response from even cytotoxic T or B cell lymphocytes with 
special focus on enhancing helper lymphocytes function as well. The peptide length is 
also important. It has been reported that longer peptides are more likely to induce a 
greater immunogenic response (41). To achieve the most desirable and specific peptide 
antigens and avoiding shared tumor specific antigens, studying the main proteins which 
are important in development and survival of CRC cell is a crucial issue. Many proteins 
are considered as good targets for making a potent peptide vaccine in CRC patients. 
One of these proteins is Survivin. Survivin which is an inhibitor of tumoral cell apoptosis, 
is a target which is used in a study conducted by Tsuruma and colleagues. This variant 
can bind to HLA-A24 and is considered to be safe (42). Some studies have used 
another common protein which is seen in CRC (43-45). They have targeted SART, a 
tumor rejection antigen. Targeting this protein has been shown to have meaningful 
correlation with clinical outcomes as well as inducing immune system response (43-45). 
Nowadays, choosing the best peptide has become easier and more cost-effective by 
use of immunoproteomics and in-silico technologies instead of experimental 
approaches (46). These bioinformatics tools are able to predict many features of 
desired peptide including the binding of peptide to MHC I and MHC II or even T cell 
receptors. Despite of using these in-silico models, the next step after synthesis of 
peptides would be to undertake preclinical tests on animal models. However, as is the 
case for other pathogens which enters human body and fight for living, tumor cells also 
have their own way for escaping immune response and result in failure of vaccination. 
Tumor cells can counter-attack cytotoxic lymphocytes by presenting FasL and induce 
lymphocytes to undergo apoptosis. Also, some tumor cells have the ability to reduce 
MHC expression and escape from recognition by immune system. Another mechanism 
which depends on tumor oncogenic pathways is production and releasing interleukins 
which are known as an inhibitor of immune system such as IL-10. Overcoming these 
issues is the cornerstone of developing a peptide vaccine. The main function of a potent 
vaccine is the appropriate stimulation of human immune response against tumors. In 
order to achieve this goal, determination of immune dominant domain epitopes is the 
first step of choosing the best peptide vaccine. These domains should have the ability to 
stimulate humeral or cellular immune system. Manipulating these peptides, in order to 
improve their affinity for MHCs, is mandatory to achieve better responses. Important 
factors for increasing the clinical response is summarized in table 2 and next chapter. 
Responding to peptide vaccines are HLA specific, which means that only those 
individual who express specific type of MHC will benefit from the vaccine and the risk of 
developing autoimmunity is still present when talking about using self-antigens.     
  
 
Adjuvant and antigen delivery system in cancer vaccination therapy 
Since peptide alone is usually insufficient to stimulate immune system to induce 
effective anti-tumor response, adjuvants are critical and required components of 
successful peptide-based vaccine strategies (47). A variety of adjuvants have been 
used in trials in treatment of various cancers. With the aim of enhancing immunogenicity 
and increasing anti-cancer immune responses adjuvants is administered with peptide in 
cancer vaccination (47). These adjuvants could be able to provide antigenic peptide 
protection from degradation and resulted in extended antigen presentation and better 
concentration, as well as an optimized availability of peptide and also higher expression 
of cytokines and co-stimulatory molecules by antigen presenting cells (APCs) (48, 49). 
As shown in figure 1, adjuvant which have been used in immunotherapy include 
cytokines such as interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and interferon (IFN), antibodies such as programmed cell death protein-1 
antibody (PD-1 Ab) and cytotoxic T-lymphocyte- associated protein-4 antibody (CTLA-4 
Ab), agonists of stimulator of interferon genes (STING) and adjuvants targeting toll-like 
receptors (TLRs) like monophospholipid A (MPLA), imiquimod, CpG, Pam3CSK4 and 
Hiltonol (known as poly-ICLC). TLRs influence their downstream signaling cascades, 
and play an important role in the immune system response (50, 51). Pam3CSK4 is a 
synthetic lipopeptide that function as a TLR2 agonist whilst Hiltonol, MPLA, imiquimod, 
and CpG activate TLR3, TLR4, TLR7/8 and TLR9, respectively (47). Based on peptide, 
cancer type, injection method, appropriate adjuvant is selected and there is not enough 
evidences that which adjuvant is superior to another. Of notice adjuvants may 
encompass desired and undesired properties. Therefore accumulated evidence of 
preclinical studies suggests that combining various adjuvants is provided more effective 
anti-tumor reaction. One possible reason for the wide differences in the reported benefit 
of anti-cancer vaccination in animal and human model of studies, may be the selection 
of safe and weak adjuvants in clinical trials in contrast to using potent adjuvants in 
animal models. On the other hand, antigen delivery systems which is also called class I 
adjuvants, besides activating the innate immune cells, through influencing several 
mechanisms promote antigen presentation to lymphocyte T cells and also increase 
antigen presentation time. Antigen delivery systems consist of incomplete Freund’s 
adjuvant (IFA), or a Montanide formulation of IFA, micro/nano particles and aluminum. 
IFA is a water-in-oil emulsion that due to provide sustained release of emulsified antigen 
could be able to induce potent cellular response and antibody protection (47). Aluminum 
is the safe and the most commonly used adjuvant and both types, aluminum phosphate 
and aluminum hydroxide, are used in human vaccines (47, 52). The main role of alum in 
vaccination can be considered as a gradual releaser of vaccine at the vaccination site. 
Moreover, this adjuvant promotes T helper-2 immune responses. Recent studies has 
shown that using alum in combination with other adjuvants can provide better and 
mixed T helper 1 and 2 response(53). Aluminum provides an antigen depot and 
activation of inflammasome in dendritic cells resulted in production of proinflammatory 
cytokines which enhances immune responses (54). Micro/nano particles could be able 
to deliver biologically active cargo into specific cell types. In addition, these small-sized 
particles protect their entities from degrading factors in serum or tissues and this 
resulted in decreased required antigen dose (55, 56). However, rapid clearance in 
plasma and the need to be combined with other adjuvants are important disadvantages 
of these small-sized particles (47). The type of induced response may be depend on 
particle size (57). Based on antigen, adjuvant and desired response micro/nano 
particles are produced from different natural or synthetic materials including collagen, 
gelatin, chitosan, poly(lactide-co-glycolide), polystyrene and poly(lactic acid) (47). 
 
Role of personalized peptide-based vaccination therapy in colorectal cancer 
Regarding the recent advances in personalized medicine, cancer therapy has 
also benefited from personalized approaches. Developing a personalized peptide 
vaccine (PPV) is almost the same as discussed above. However, there are some 
important steps prior to vaccine development. During the development of a PPV, pre-
existing immunity to TAAs is the most important issue. In order to achieve this goal, 
individual’s serum will be tested for different immunogenic MHC I epitopes from different 
TAAs. The patient’s vaccine will be mainly based on one to four of these peptides (11). 
The reason behind choosing multiple antigen is the unavailability of most of tumors for 
characterization before treatment. Choosing more specific antigens will guarantee a 
better response (18). Kibe et al. has conducted a phase II clinical trial on PPV in CRC 
patients. They have selected four HLA matched antigens which were individually 
selected from a pool of candidate peptides. They have reported a favorable outcomes 
and survival benefits in patients with advanced CRC who have been previously failed 
their treatment (43). While not all of their patients responded well to therapy, they tried 
to introduce a prognostic and predictive biomarker for their patients. They have reported 
that lower B-cell activating factor and higher IL-6, interferon gamma inducible protein-10 
level prior to vaccination is related to worse survival. Sato has also conducted a similar 
study on CRC patients (58). They have chosen 4 peptides among their candidate panel 
of antigens applicable for vaccination and administered them along with 5-fluorouracil 
derivative. They concluded that 80mg/m2/day of 5-fluorouracil derivative in combination 
with the vaccine will successfully augment cytotoxic T lymphocyte activity (58). Another 
study by Hattori et al. evaluated the effect of PPV and UFT and UZEL in metastatic 
CRC. They have prepared 25 and 23 peptides for HLA-A24+ and HLA-A2+ patients 
respectively. These peptides were identified by reverse immunology techniques or by 
cloned TAA genes. None of their patient’s showed complete or even partial response 
and only 6 out of 14 patients had stable disease. However, combination of peptide 
vaccine and, UFT and UZEL was well tolerated and provided humeral and cellular 
response (59). Rahma et al. have also conducted three arms clinical study on 38 CRC 
patients and used mutant ras vaccine as a PPV (60). These peptides has the 
potentiality of inducing specific immune response along with adjuvants. They have 
suggested that using IL-2 as adjuvant may have negative effect on immune response 
induced by ras peptide vaccination (60). According to available results and hopeful 
results from phase I and II clinical trials, still we face lack of enough evidence to 
conclude the effectiveness PPV in improving the survival and more phase III clinical 
trials are warranted.  
 Conclusion and future prospective 
There is a growing trend toward developing new cancer treatment and the 
vaccines seems to be an attractive approach for immunologists, oncologists, molecular 
geneticists and molecular engineering. Constructing different types of cancer vaccines, 
especially PPVs, requires a multidisciplinary team and a good research background for 
providing the best pool antigens. Recently, there are a growing number of completed 
phase I and II clinical trials for PPVs in CRC patients mostly with advanced and 
metastatic tumors. However, lack of phase III clinical trials is still highlighted in the 
literature. It also seems that some important issues are neglected in the literature which 
should be addressed in further researches. The most important topic stands for the 
interoperation of individual study results. In most of the studies it is still unclear why 
some patients don’t respond well to PPVs while the others do so. More focusing on 
specific personalized differences in term of immune system genetic differences such as 
possible polymorphism or mutations may provide some answers for individual 
responses to same PPVs. Also, the role of microRNAs as an important prognostic and 
predictive markers in CRC is not evaluated in personalized response to PPVs. 
Researchers should also pay attentions to combination therapy of PPVs and newer 
therapeutic biomarkers such as targeting tumor microenvironment (61, 62). It’s not clear 
even combination of different adjuvants can provide better responses in those patients 
who did not responded to PPVs. Another issue which should be addressed is 
prophylactic vaccination in CRC patients. While most of the studies have focused on 
advanced and poor responding CRC, it is not clear whether PPV vaccinations is helpful 
in slowing the progression of CRC or inhibiting some CRC phenotypes such as colon 
polyps. 
  
Figure 1. Adjuvants (blue circle) and delivery systems (yellow circle) for improvement of 
cancer vaccines efficacy 
 
 
Figure 2. Peptide-based and personalized peptide-based vaccination therapy. The 
peptide antigen is first uptake by dendritic cells and the processed protein will be 
presented to immune system cells including cytotoxic T cells. After activation, these 
cells will kill tumor cells by inducing apoptosis and producing specific chemokine. During 
personalized base peptide vaccine therapy, a more specific response is expected. After 
mutation determination in tumoral patient, successful HLA typing is mandatory for 
producing an effective vaccine. The most effective peptide can be chosen by use of 
different software which are able to predict the efficacy of HLA-Peptide-TCR complex. 
Vast number of adjuvants are available for boosting the effect of personalized based 
vaccines which can be used along with vaccination. The immune monitoring will 
guarantee the efficacy of desired peptide vaccine in each individual. 
 
Table 1. Personalized peptide vaccine in contrast to other common vaccines.  
Vaccine type Advantages Disadvantages 
Traditional peptide vaccine 
Inexpensive and easy to produce 
Shorter preparation time 
Reduced chance of adverse 
immune reaction 
cytotoxic T lymphocyte induction 
Slow immune response 
No memory T cell 
Induction of primary 
immune response  
Personalized peptide vaccine 
Faster and stronger response 
cytotoxic T lymphocyte induction 
Memory T cell activation 
Not inducing primary immune 
response 
Expensive and more time 
consuming  
Longer preparation time 
Not inducing regulatory T 
cells 
 Table 2. Summary of the most relevant studies investigating peptide-based and personalized peptide-based vaccination therapy in 
colorectal cancer 
Author and 
year 
Study 
phase Peptide vaccine Adjuvant Sample Main side effect(s)  Main finding 
Goydos et 
al., 1996 (63) Phase I mucin MUC-1 BCG 30 CRC 
Injection-site 
reaction,  fever 
Profound delayed-type hypersensitivity to peptide 
vaccine observed and the vaccine was tolerated 
well. However they have failed to achieve tumor 
response in their trial.  
Gonzalez et 
al., 1998 (64) - hu-EGF 
Aluminium 
hydroxyde 4 CRC 
Injection-site 
reaction 
The vaccine was well tolerated and increased 
antibody against peptide was noted 
Miyagi et al., 
2001 (44) Phase I 
SART3 109-118 and 
SART3 315-323 Montanide 
12 advanced 
CRC 
Injection-site 
reaction 
Increased T cell response in those with HLA-A24+ 
colon cancer cells. The highest dose achieved the 
best response.  
Moulton et 
al., 2002 (65) Phase II 
β-hCG (CTP37) 
conjugated to diphtheria 
toxoid 
Mannide 
monooleate, 
nor-muramyl 
dipeptide 
77 stage IV 
CRC 
Injection-site 
reaction 
Anti-hCG antibody production was related to better 
survival with adequate safety issues 
Mazzaferro 
et al., 2003 
(66) 
- autologous tumor-derived HSPPC-96 - 
29 CRC with 
liver metastases 
No serious adverse 
events 
Significant cytotoxic T cell response was noted. 
Improvement in OS and DFS in patients with anti-
tumor response 
Tsuruma et 
al., 2004 (67) Phase I survivin-2B80-88 - 
17 HLA-A*2402 
positive CRC 
No serious adverse 
events 
Survivin-2B80-88 was safe however peptide alone 
did not elicit overt clinical response  
Sato et al., 
2004 (45) Phase I SART, CyB, Ick, ART Montanide 
10 advanced 
CRC with HLA-
A24+ 
Injection-site 
reaction 
The combination of these four peptide vaccine was 
safe. Antigen specific immunity and clinical 
response was noted.  
Mukherjee et 
al., 2007 (68) 
Preclinic
al 
Two MHC I-restricted 
MUC1 peptides, and, 
one MHC II helper 
peptide, 
mouse unmethylated 
CpG 
oligodeoxynucleotide 
constructs, GM-CSF 
IFA 
MC38 colon 
cancer 
cell line 
expressing full-
length human 
MUC1 into 
human 
MUC1.Tg mice 
- 
Immunization resulted in robust anti-tumor 
response. cytotoxic and IFN-γ producing CD4+ 
lymphocytes against MUC1  
Tan et al., 
2007 (69) 
Preclinic
al 
Porcine and murine 
endoglin proteins  
pEDG and mEDG 
- 
CT26 colon 
carcinoma mice 
model 
- 
DNA vaccine along with mentioned peptides 
yielded a therapeutic effect better than using them 
alone 
Seledtsov et Phase I- xenogenic polyantigenic - 37 CRC stage Injection-site Xenogenic tumor associated antigens were safe 
al., 2007 (70) II vaccine  (B16 and LLC 
cells, as well as B6 SCs) 
IV reaction and has the ability to induce cellular and humoral 
response 
Kaumaya et 
al., 2009 (71) Phase I 
B-cell epitopes of HER2 
extracellular domain,  
promiscuous T-cell 
epitope 
Nor-
muramyl-
dipeptide, 
Montanide 
24 metastatic 
and/or recurrent 
solid tumors 
No serious adverse 
events 
Successfully elicited antibody response in more 
than half of patients 
Okuno et al., 
2014 (72) 
Phase 
Ib 
RNF43, TOMM34, 
FOXM1 MELK, HJURP, 
VEGFR1, VEGFR2 
UFT/LV, 
ISA-51VG, 
Montanide 
30 
nonresectable 
mCRC with 
HLAA*2402-
positive 
Injection-site 
reaction 
Patients who showed cytotoxic T cell response has 
longer survival 
Kibe et al., 
2014 (43) Phase II 
CypB, EGFR, EZH2, 
NRPL, p56Lck, 
ppMAPkkk, MRP3, PAP, 
PSA, PSMA, PTHrP, 
SART2, SART3, 
UBE2V, WHSC2 
Montanide 60 advanced CRC 
Injection-site 
reaction, anemia, 
lymphopenia 
Increased peptide specific cytotoxic T cells were 
related to favorable OS  
Rahma et al., 
2014 (60) - 
13-mer peptides 
(residues 5-17) 
corresponding to the 
tumor Ras mutations 
IL-2, GM-
CSF, Detox 
38 advanced 
CRC with 
different ras 
mutations 
 
Fever, fatigue, 
injection-site 
reaction 
Peptides and adjuvants successfully induced 
specific immune response with proposing that 
adjuvant may have negative effect on immune 
response 
Murahashi et 
al., 2016 (73) Phase I 
KOC1, DEPDC1, 
MPHOSPH1, TTK, 
URLC10 with escalating 
cyclophosphamide   
IL-2 
Montanide, 
ISA-51VG 
9 advanced 
CRC with HLA-
A2402-positive 
Injection-site 
reaction 
TAA-specific T lymphocyte responses was related 
to longer survival. Furthermore, higher reduction in 
regulatory T lymphocytes were correlated with 
better survival  
Correale et 
al., 2016 (74) 
Phase 
Ib 
poly-epitope peptide 
vaccination to 
thymidylate synthase 
immune-
adjuvant IG-
1, GOLFIG 
chemo-
immunothera
py 
29 mCRC Injection-site reaction, anemia 
Peptide vaccine alone or in combination with 
adjuvant and chemotherapy showed anti-tumor 
activity. The combination group showed better 
survival although adverse event was noted 
Goodwin et 
al., 2017 (75) 
Preclinic
al 
Colon cancer peptide 
antigen (p-AH1-A5) 
CpG, 
2′3′cGAMP, 
5′pppdsRNA, 
LCP 
nanoparticle 
Female BALB/c 
mice - 
All 3 adjuvant resulted in proinflammatory response 
but only 5′pppdsRNA was able to achieve an anti-
cancer response 
Taniguchi et 
al., 2017 (76) Phase I 
OCV-C02 consists of 
two peptides, RNF43-
721 and TOMM34-299  
Montanide 
24 advanced or 
relapsed CRC 
with HLA-
Injection-site 
reaction 
OCV-C02 was safe and well tolerated with no 
dose-limiting toxicity 
A*24:02 positive  
and no 
chemotherapeut
ic response 
Kawamura et 
al., 2018 (77) Phase II 
HLA-A*2402-restricted 
RNF43 and TOMM34 
UFT/LV, 
ISA-51, 
Montanide 
44 stage III CRC Injection-site reaction 
Vaccine induced immune response and provided 
survival benefits 
CRC; colorectal cancer; mCRC: metastatic colorectal cancer; OS: overall survival; DFS: disease-free survival; hCG: human chorionic gonadotropin; TSPP: poly-
epitope peptide vaccination to thymidylate synthase; MTD: maximal tolerated dose; IFN: interferon; HLA: Human leukocyte antigen; LCP: lipid calcium 
phosphate; IFA: incomplete freund’s adjuvant 
 
 
Abbreviations: 
APC: antigen presenting cells 
CEA: carcinoembryonic antigen 
CRC: colorectal cancer 
CTLA-4 Ab: cytotoxic T-lymphocyte- associated protein-4 antibody 
DC: dendritic cells 
DCVs: Dendritic cell vaccines 
DFS: disease-free survival 
GM-CSF: granulocyte-macrophage colony-stimulating factor 
hCG: human chorionic gonadotropin 
HLA: Human leukocyte antigen 
IFA: imiquimod Freund’s adjuvant  
IFA: incomplete freund’s adjuvant 
IFN: interferon 
IFN: interferon 
LCP: lipid calcium phosphate 
mCRC: metastatic colorectal cancer 
MPLA: monophospholipid A 
MTD: maximal tolerated dose 
OS: overall survival 
PD-1 Ab: death protein-1 antibody 
PPV: personalized peptide vaccine 
STING: stimulator of interferon genes 
TAA: tumor associated antigens 
TLR: toll-like receptors 
TSPP: poly-epitope peptide vaccination to thymidylate synthase 
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